1. Home
  2. VGZ vs AGEN Comparison

VGZ vs AGEN Comparison

Compare VGZ & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vista Gold Corp

VGZ

Vista Gold Corp

HOLD

Current Price

$2.59

Market Cap

360.5M

Sector

N/A

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$6.16

Market Cap

335.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGZ
AGEN
Founded
1983
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
360.5M
335.6M
IPO Year
1996
1999

Fundamental Metrics

Financial Performance
Metric
VGZ
AGEN
Price
$2.59
$6.16
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $26.33
AVG Volume (30 Days)
★ 2.2M
999.0K
Earning Date
11-11-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 100.00
EPS
N/A
★ 0.96
Revenue
N/A
★ $42,877,086.00
Revenue This Year
N/A
$9.64
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$6.57
Revenue Growth
N/A
★ 89.95
52 Week Low
$1.43
$2.71
52 Week High
$3.13
$10.19

Technical Indicators

Market Signals
Indicator
VGZ
AGEN
Relative Strength Index (RSI) 49.56 37.85
Support Level $2.51 $6.18
Resistance Level $2.66 $8.64
Average True Range (ATR) 0.11 0.41
MACD -0.02 -0.12
Stochastic Oscillator 33.19 13.66

Price Performance

Historical Comparison
VGZ
AGEN

About VGZ Vista Gold Corp

Vista Gold Corp operates as a development-stage company in the gold mining industry. Its flagship asset is the Mt Todd Gold Project, a development-stage gold deposit located in the Tier-1 jurisdiction of Northern Territory, Australia. Mt Todd offers a large gold mineral reserve, development optionality, expansion opportunities, exploration upside, local infrastructure, community support, and demonstrated economic feasibility. It operates in one reportable segment, consisting of acquisition, exploration and evaluation activities which are focused on Australia.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: